Dr. Grey AI

Acute Respiratory Distress Syndrome

Research on ARDS, a severe lung condition with hypoxemic respiratory failure. Includes treatments for COVID-19-associated ARDS, sepsis-related ARDS, and mechanical ventilation support.

Quick Answer

What it is

Research on ARDS, a severe lung condition with hypoxemic respiratory failure. Includes treatments for COVID-19-associated ARDS, sepsis-related ARDS, and mechanical ventilation support.

Key findings

  • Grade A: ARDS/Respiratory Failure (Vasoactive Intestinal Peptide (VIP/Aviptadil))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

鈩癸笍 Quick Facts

Quick Facts: Acute Respiratory Distress Syndrome

  • Supplements Studied:1
1 supps 路 1 outcomes

Detailed Outcomes

A
ARDS/Respiratory Failure
Mixed results: Small RCT (n=196) showed improved 60-day survival with IV aviptadil vs placebo. Larger TESICO trial (n=461) found no difference in primary endpoint (alive and free from respiratory failure at day 60). Clinical benefit uncertain.
none

Research Citations (53)

Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.
(2025)
PMID: 41368449
Aviptadil as a Promising Intervention: A Case Study for Transfusion-Related Acute Lung Injury Treatment in a Cardiac Patient.
(2024)
PMID: 38458826
Vasoactive Intestinal Polypeptide for Patients Hospitalized With COVID-19 and Hypoxemic Respiratory Failure: Effect on Mortality-The TESICO Trial
(2023)
PMID: 37328169
Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice.
(2023)
PMID: 36650220
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
(2023)
PMID: 37348524
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
(2022)
PMID: 36193478
Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.
(2022)
PMID: 35018346
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
(2022)
PMID: 36044317
Editorial: GPCR in Inflammatory and Cancer Diseases.
(2020)
PMID: 33101216
Vasoactive Intestinal Peptide Changes the Frequency and Force of Myocardial Contraction in Rats.
(2020)
PMID: 33098516

Related Conditions

Rheumatoid Arthritis (RA)

1 shared supplement 路 67 outcomes

Rheumatoid arthritis (RA) is an autoimmune disease that is mainly known for affecting the joints, but can also affect other parts of the body. It is more common in women than men and often starts during middle age, but it can occur at any age. The cause of RA is not well understood, but it seems to involve genetic, environmental, and hormonal factors.

Pulmonary Hypertension

1 shared supplement 路 3 outcomes

Pulmonary hypertension is high blood pressure in the arteries leading from the heart to the lungs. These arteries become hard and narrow, forcing the heart to work harder to pump blood through. Symptoms include shortness of breath, chest pain, a racing heartbeat, and fatigue.

Inflammatory Bowel Disease (IBD)

1 shared supplement 路 7 outcomes

Inflammatory bowel disease (IBD) describes a group of gastrointestinal conditions characterized by chronic inflammation that damages the intestinal lining. Common symptoms include diarrhea, unexplained weight loss, abdominal pain, bloating, and fatigue. The cause of IBD is unknown, but researchers believe it is likely an autoimmune disease that develops due to interactions between the immune system, genes, gut microbiome, and certain lifestyle factors. There is no cure, but IBD can be managed with lifestyle modifications, medications, intermittent bowel rest, and surgery.